Effect of cannabinoid receptor agonists on streptozotocin-induced hyperalgesia in diabetic neuropathy

Pharmacology

Volumn 82, Issue 3, 2008, Pages 193-200

  Bujalska, Magdalena ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

AM1241; Cannabinoid system; CB 1 and CB 2 receptors; Diabetes; Hyperalgesia; Indomethacin; L NOArg; Met F AEA; Streptozotocin; WIN 55,212 2

Indexed keywords

2 METHYLARACHIDONOYL 2' FLUOROETHYLAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; ARACHIDONIC ACID DERIVATIVE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; INDOMETACIN; N(G) NITROARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETIC NEUROPATHY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; HYPERALGESIA; MALE; MONOTHERAPY; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; RAT; TREATMENT RESPONSE;

ANALGESICS; ANIMALS; ARACHIDONIC ACIDS; BENZOXAZINES; CANNABINOIDS; CYCLOOXYGENASE INHIBITORS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HYPERALGESIA; INDOMETHACIN; MALE; MORPHOLINES; NAPHTHALENES; NITRIC OXIDE SYNTHASE; NITROARGININE; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; STREPTOZOCIN;

EID: 52049099155     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000156485     Document Type: Article

References (31)

1. Azad SC, Rammes G: Cannabinoids in anaesthesia and pain therapy. Curr Opin Anaesthesiol 2005;18:424-427.
2. Palmer SL, Thakur GA, Makriyannis A: Cannabinergic ligands. Chem Phys Lipids 2002;121:3-19.
3. Goya P, Jagerovic N, Hernandez-Folgado L, Martin MI: Cannabinoids and neuropathic pain. Mini Rev Med Chem 2003;3:765-772.
4. Rice ASC, Farquhar-Smith WP, Nagy I: Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostagl Leukotr Essent Fatty Acids 2002;66:234-256.
5. Hohmann AG: Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids 2002;121:173-190.
6. Pertwee RG: Cannabinoid receptors and pain. Prog Neurobiol 2001;63:569-611.
7. Nakhoda A, Wong HA: The induction of diabetes in rats by intramuscular administration of streptozotocin. Experientia 1979;35:1679-1980.
8. Randall LO, Selitto JJ: A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 1957;111:409-419.
9. Tallarida RJ, Murray RB: Manual of Pharmacologic Calculation with Computer Programs, ed 2. New York, Springer, 1986, pp 113-117.
10. Richardson JD, Aanonsen L, Hargreaves KM: Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 1998;345:145-153.
11. Seidel K, Hamza M, Ates M, Gühring H: Flurbiprofen inhibits capsaicin-induced calcitonin gene-related peptide release from rat spinal cord via an endocannabinoid-dependent mechanism. Neurosci Lett 2003;338:99-102.
12. Hama A, Sagen J: Antinociceptive effect of cannabinoid agonist WIN 55,212-2 in rats with a spinal cord injury. Exp Neurol 2006;204:454-457.
13. Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L, James I: The role of central and peripheral cannabinoid 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 2001;92:91-100.
14. Bridges D, Ahmad K, Rice ASC: The synthetic cannabinoid WIN 55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol 2001;133:586-594.
15. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, Vanderah TW, Lai J, Porreca F, Makriyannis A, Malan TP Jr: Activation of CB 2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 2003;100:10529-10533.
16. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, Davar G, Makriyannis A, Vanderah TW, Mata HP, Malan TP Jr: CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 2005;102:3093-3098.
17. Scott DA, Wright CE, Angus JA: Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain 2004;109:124-131.
18. Costa B, Colleoni M, Conti S, Trovato AE, Bianchi M, Sotgiu ML, Giagnoni G: Repeated treatment with the synthetic cannabinoid WIN,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain. Br J Pharmacol 2004;141:4-8.
19. Zhang F, Hong S, Stone V, Smith PJ: Expression of cannabinoid CB1 Receptors in models of diabetic neuropathy. J Pharmacol Exp Ther 2007;323:508-515.
20. Ulugöl A, Karadag HC, Ipci Y, Tamer M, Dokmeci I: The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats. Neurosci Lett 2004;371:167-170.
21. Doǧrul A, Gucombining double acute accentl H, Yildiz O, Biling F, Gucombining double acute accentzeldemir E: Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect. Neurosci Lett 2004;368:82-86.
22. Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S, Reggiani A: CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 2006;23:1530-1538.
23. Bingham B, Jones PG, Uveges AJ, Kotnis S, Lu P, Smith VA, Sun SC, Resnick L, Chlenov M, He Y, Strassle BW, Cummons TA, Piesla MJ, Harrison JE, Whiteside GT, Kennedy JD: Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2)-selective ligand AM1241 and its resolved enantiomers. Br J Pharmacol 2007;151:1061-1070. Erratum in: Br J Pharmacol 2007;151:1137.
24. Bujalska M, Tatarkiewicz J, deCorde A, Gumułka W: Effect of cyclooxygenase and nitric oxide synthase inhibitors on streptozotocin-induced hyperalgesia in rats. Pharmacology 2008;81:151-157.
25. Ates M, Hamza M, Seidel K, Kotalla CE, Ledent C, Gühring H: Intrathecally applied flurbiprofen produces an endocannabinoid-dependent antinociception in the rat formalin test. Eur J Neurosci 2003;17:597-604.
26. Guindon J, De Léan A, Beaulieu P: Local interaction between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal antinflammatory drug, in acute and inflammatory pain. Pain 2006;121:85-93.
27. Molina-Holgado F, Pinteaux E, Moore JD, Molina-Holgado E, Guaza C, Gibson RM, Rothwell NJ: Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci 2003;23:6470-6474.
28. Hillard CJ, Muthian S, Kearn CS: Effects of CB(1) cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity. FEBS Lett 1999;459:277-281.
29. Coffey RG, Snella KJ, Pross S: Inhibition of macrophage nitric oxide production by tetrahydrocannabinol in vivo and in vitro. Int J Immunopharmacol 1996;18:749-752.
30. Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M: The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol 2007;556:75-83.
31. Gühring H, Hamza M, Sergejeva M, Ates M, Kotalla CE, Ledent C, Brune K: A role for endocannabinoids in indomethacin-induced spinal antinociception. Eur J Pharmacol 2002;454:153-163.